🇺🇸 I131 in United States
20 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 20
Most-reported reactions
- Dacryostenosis Acquired — 4 reports (20%)
- Lacrimation Increased — 4 reports (20%)
- Hypothyroidism — 3 reports (15%)
- Diarrhoea — 2 reports (10%)
- Venoocclusive Liver Disease — 2 reports (10%)
- Abdominal Discomfort — 1 report (5%)
- Areflexia — 1 report (5%)
- Atrial Fibrillation — 1 report (5%)
- Blood Calcium Decreased — 1 report (5%)
- Blood Potassium Decreased — 1 report (5%)
Other Oncology approved in United States
Frequently asked questions
Is I131 approved in United States?
I131 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for I131 in United States?
Gustave Roussy, Cancer Campus, Grand Paris is the originator. The local marketing authorisation holder may differ — check the official source linked above.